https://www.biopharmawatch.com/news/SRRK/scholar-rock-fda-review-apitegromab-sma BiopharmaWatch en 2026-08-07T20:20:00.000Z Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress with Second Fill-Finish Facility; Approval Decision Anticipated by September 30, 2026 Action Date https://www.biopharmawatch.com/news/KNSA/kiniksa-pharmaceuticals-canaccord-growth-conference-2026 BiopharmaWatch en 2026-08-07T20:08:14.609Z Kiniksa Pharmaceuticals to Present at Canaccord Genuity 46th Annual Growth Conference https://www.biopharmawatch.com/news/ATYR/atyr-pharma-q2-2026-results-efzofitimod-prioritization BiopharmaWatch en 2026-08-07T20:01:00.000Z aTyr Pharma Announces Second Quarter 2026 Results, Program Prioritization and Corporate Restructuring to Support Efzofitimod Program in ILD https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-conference-call-fda-review BiopharmaWatch en 2026-08-07T20:01:00.000Z NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Host Conference Call August 10 to Discuss FDA First-Cycle ANDA Review and Commercial Plans https://www.biopharmawatch.com/news/IMCC/im-cannabis-raises-250000-convertible-note-financing BiopharmaWatch en 2026-08-07T20:01:00.000Z IM Cannabis Raises US$250,000 of Gross Proceeds in Convertible Note Financing https://www.biopharmawatch.com/news/GRAL/grail-fda-advisory-meeting-galleri-test-review BiopharmaWatch en 2026-08-07T15:05:00.000Z GRAIL Announces FDA Advisory Committee Meeting to Review Premarket Approval Application for the Galleri® Multi-Cancer Early Detection Test https://www.biopharmawatch.com/news/FEMY/femasys-secures-30-million-private-placement BiopharmaWatch en 2026-08-07T13:25:00.000Z Femasys Secures $30 Million Private Placement, with Potential Proceeds of Up to $90 Million https://www.biopharmawatch.com/news/RCEL/avita-medical-participation-canaccord-genuity-conference BiopharmaWatch en 2026-08-07T12:45:00.000Z AVITA Medical Announces Participation at Canaccord Genuity Growth Conference https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-q2-2026-financial-results-update BiopharmaWatch en 2026-08-07T12:45:00.000Z Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update https://www.biopharmawatch.com/news/XBIO/xenetic-biosciences-q2-2026-results-dnase-platform BiopharmaWatch en 2026-08-07T12:35:00.000Z Xenetic Biosciences Reports Second Quarter 2026 Financial Results and Highlights Strengthened Scientific Foundation Supporting Continued Advancement of Proprietary DNase Platform https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-corporate-update-q2-2026 BiopharmaWatch en 2026-08-07T12:30:00.000Z Quoin Pharmaceuticals to Announce Corporate Update and Second Quarter 2026 Financial Results on Friday, August 14, 2026 https://www.biopharmawatch.com/news/NBIX/neurocrine-phase-1-study-nbip-1968-obesity BiopharmaWatch en 2026-08-07T12:30:00.000Z Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'1968, a GLP-1/GIP/Glucagon Receptor Triple Agonist https://www.biopharmawatch.com/news/LTRN/lantern-pharma-q2-2026-results-report BiopharmaWatch en 2026-08-07T12:00:00.000Z Lantern Pharma to Report Second Quarter 2026 Operating & Financial Results on August 14th, 2026 at 9:00 a.m. ET https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-q2-2026-results-cypath-lung BiopharmaWatch en 2026-08-07T12:00:00.000Z bioAffinity Technologies Reports Second Quarter 2026 Results and Continued Strong Commercial Momentum for CyPath® Lung https://www.biopharmawatch.com/news/HUMA/humacyte-announces-q2-2026-financial-results BiopharmaWatch en 2026-08-07T12:00:00.000Z Humacyte To Announce 2026 Second Quarter Financial Results and Provide Business Update on August 12, 2026 https://www.biopharmawatch.com/news/LFWD/lifeward-report-q2-2026-results-august-14 BiopharmaWatch en 2026-08-07T12:00:00.000Z Lifeward to Report Second Quarter 2026 Financial Results on August 14, 2026 https://www.biopharmawatch.com/news/FTH/faeth-therapeutics-presents-pk-pd-modeling-piktor-trial BiopharmaWatch en 2026-08-07T11:30:00.000Z Faeth Therapeutics to Present PK/PD Modeling That Informed PIKTOR Dose Selection in Ongoing FTH-PIK-201 Trial at Upcoming Scientific Conference https://www.biopharmawatch.com/news/SNGX/soligenix-second-quarter-2026-financial-results BiopharmaWatch en 2026-08-07T11:30:00.000Z Soligenix Announces Recent Updates and Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/TMCI/treace-medical-concepts-q2-2026-results BiopharmaWatch en 2026-08-07T11:05:00.000Z Treace Medical Concepts Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/KPRX/kiora-pharmaceuticals-q2-2026-financial-results-update BiopharmaWatch en 2026-08-07T11:00:00.000Z Kiora Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/NHC/nhc-reports-second-quarter-2026-earnings BiopharmaWatch en 2026-08-07T11:00:00.000Z NHC Reports Second Quarter 2026 Earnings https://www.biopharmawatch.com/news/NRXP/fda-first-cycle-review-preservative-free-ketamine BiopharmaWatch en 2026-08-07T11:00:00.000Z FDA Completes First-Cycle Review of Preservative-Free Ketamine ANDA with No Drug Related Major Deficiencies; Final Packaging Certification Requested for Approval https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-q2-2026-financial-results BiopharmaWatch en 2026-08-07T11:00:00.000Z Minerva Neurosciences Provides Second Quarter 2026 Financial Results and Business Updates https://www.biopharmawatch.com/news/GYRE/gyre-therapeutics-q2-2026-financial-results-update BiopharmaWatch en 2026-08-07T11:00:00.000Z Gyre Therapeutics Reports Second Quarter 2026 and Year-to-Date Financial Results and Provides Business Update https://www.biopharmawatch.com/news/RPID/rapid-micro-biosystems-q2-2026-results BiopharmaWatch en 2026-08-07T11:00:00.000Z Rapid Micro Biosystems Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-record-q2-2026-results BiopharmaWatch en 2026-08-07T10:50:00.000Z ANI Pharmaceuticals Reports Record Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/NHC/nhc-announces-common-dividend BiopharmaWatch en 2026-08-07T00:00:00.000Z NHC Announces Common Dividend https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-executive-chair-transition BiopharmaWatch en 2026-08-06T22:24:00.000Z Tango Therapeutics Announces Executive Chair Transition https://www.biopharmawatch.com/news/BIIB/biogen-acquisition-raythera-immunology-assets BiopharmaWatch en 2026-08-06T22:15:00.000Z Biogen Completes Acquisition of RayThera Inc. https://www.biopharmawatch.com/news/NUTX/nutex-health-second-quarter-2026-financial-results BiopharmaWatch en 2026-08-06T21:58:00.000Z NUTEX HEALTH REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS https://www.biopharmawatch.com/news/LMAT/lemaitre-participate-needham-conference BiopharmaWatch en 2026-08-06T21:15:00.000Z LeMaitre to Participate in the 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference https://www.biopharmawatch.com/news/ZNTL/zentalis-pharmaceuticals-q2-2026-results BiopharmaWatch en 2026-08-06T21:05:30.769Z Zentalis Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Updates https://www.biopharmawatch.com/news/ACRS/aclaris-fast-track-modzatinib-lichen-planus BiopharmaWatch en 2026-08-06T21:04:33.797Z Aclaris Therapeutics Receives Fast Track Designation for Modzatinib (ATI-2138) for Moderate to Severe Lichen Planus (LP) https://www.biopharmawatch.com/news/RMD/resmed-q4-fy2026-results BiopharmaWatch en 2026-08-06T21:01:05.826Z Resmed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2026 https://www.biopharmawatch.com/news/ICCC/immucell-announces-financial-results-q2-2026 BiopharmaWatch en 2026-08-06T20:58:43.642Z ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2026 https://www.biopharmawatch.com/news/NEPH/nephros-financial-results-q2-2026 BiopharmaWatch en 2026-08-06T20:58:29.644Z Nephros Announces Strong Financial Results for Quarter Ended June 30, 2026 https://www.biopharmawatch.com/news/CTMX/cytomx-q2-2026-financial-results-business-update BiopharmaWatch en 2026-08-06T20:57:55.220Z CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/OCS/oculis-q2-2026-financial-results-update BiopharmaWatch en 2026-08-06T20:57:09.775Z Oculis Reports Q2 2026 Financial Results and Provides Company Update https://www.biopharmawatch.com/news/ICUI/icu-medical-q2-2026-results-guidance-update BiopharmaWatch en 2026-08-06T20:56:28.385Z ICU Medical Announces Second Quarter 2026 Results and Updates its Fiscal Year 2026 Guidance https://www.biopharmawatch.com/news/ORGO/organogenesis-q2-2026-financial-results BiopharmaWatch en 2026-08-06T20:56:14.642Z Organogenesis Holdings Inc. Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-q2-2026-financial-results BiopharmaWatch en 2026-08-06T20:55:58.991Z Trevi Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates https://www.biopharmawatch.com/news/ARTV/artiva-biotherapeutics-q2-2026-results BiopharmaWatch en 2026-08-06T20:55:01.545Z Artiva Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-q2-2026-results BiopharmaWatch en 2026-08-06T20:48:07.303Z Denali Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights https://www.biopharmawatch.com/news/INAB/in8bio-reports-q2-2026-results-highlights BiopharmaWatch en 2026-08-06T20:47:08.109Z IN8bio Reports Second Quarter 2026 Financial Results and Recent Business Highlights https://www.biopharmawatch.com/news/TECX/tectonic-therapeutic-q2-2026-results-business-highlights BiopharmaWatch en 2026-08-06T20:46:15.827Z Tectonic Therapeutic Announces Second Quarter 2026 Financial Results and Recent Business Highlights https://www.biopharmawatch.com/news/REPL/fda-accelerated-approval-tudriqev-melanoma BiopharmaWatch en 2026-08-06T20:45:32.133Z Replimune Announces FDA Accelerated Approval of TUDRIQEVTM in Combination with Nivolumab for Unresectable Advanced Cutaneous Melanoma After Progression on an anti-PD-1 Based Regimen https://www.biopharmawatch.com/news/APYX/apyx-medical-q2-2026-financial-results BiopharmaWatch en 2026-08-06T20:44:09.042Z Apyx Medical Corporation Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/CVRX/cvrx-reports-q2-2026-financial-results BiopharmaWatch en 2026-08-06T20:43:53.232Z CVRx Reports Second Quarter 2026 Financial and Operating Results https://www.biopharmawatch.com/news/CON/concentra-group-holdings-q2-2026-results BiopharmaWatch en 2026-08-06T20:31:00.000Z Concentra Group Holdings Parent, Inc. Announces Results For Its Second Quarter Ended June 30, 2026 and Raises FY 2026 Guidance https://www.biopharmawatch.com/news/MGTX/meiragtx-inducement-grant-nasdaq-listing-rule-5635c4 BiopharmaWatch en 2026-08-06T20:30:32.000Z MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/CLLS/cellectis-reports-financial-results-q2-2026 BiopharmaWatch en 2026-08-06T20:30:00.000Z Cellectis Reports Financial Results for the Second Quarter 2026 https://www.biopharmawatch.com/news/CTSO/cytosorbents-q2-2026-financial-results-regulatory-update BiopharmaWatch en 2026-08-06T20:25:00.000Z CytoSorbents Reports Second Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update https://www.biopharmawatch.com/news/XFOR/x4-pharmaceuticals-q2-2026-results-update BiopharmaWatch en 2026-08-06T20:15:33.000Z X4 Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/REVB/revelation-biosciences-financial-results-q2-2026 BiopharmaWatch en 2026-08-06T20:15:00.000Z Revelation Biosciences, Inc. Announces Financial Results For the Three and Six Months Ended June 30, 2026 https://www.biopharmawatch.com/news/GMED/globus-medical-reports-q2-2026-results BiopharmaWatch en 2026-08-06T20:15:00.000Z Globus Medical Reports Second Quarter 2026 Results https://www.biopharmawatch.com/news/AMN/amn-healthcare-q2-2026-results BiopharmaWatch en 2026-08-06T20:15:00.000Z AMN HEALTHCARE ANNOUNCES SECOND QUARTER 2026 RESULTS https://www.biopharmawatch.com/news/PROF/profound-medical-q2-2026-financial-results BiopharmaWatch en 2026-08-06T20:12:00.000Z Profound Medical Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/SLDB/solid-biosciences-q2-2026-financial-results BiopharmaWatch en 2026-08-06T20:08:00.000Z Solid Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Updates https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-q2-2026-results-update BiopharmaWatch en 2026-08-06T20:06:17.000Z Phio Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update https://www.biopharmawatch.com/news/LYEL/lyell-immunopharma-q2-2026-results BiopharmaWatch en 2026-08-06T20:05:57.000Z Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026 https://www.biopharmawatch.com/news/GPCR/structure-therapeutics-q2-2026-results-highlights BiopharmaWatch en 2026-08-06T20:05:56.000Z Structure Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights https://www.biopharmawatch.com/news/PLSE/pulse-biosciences-business-updates-q2-2026 BiopharmaWatch en 2026-08-06T20:05:00.000Z Pulse Biosciences Reports Business Updates and Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/ARDX/ardelyx-q2-2026-financial-results-update BiopharmaWatch en 2026-08-06T20:05:00.000Z Ardelyx Reports Second Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/ALEC/alector-reports-q2-2026-results-business-update BiopharmaWatch en 2026-08-06T20:05:00.000Z Alector Reports Second Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-q2-2026-financial-results BiopharmaWatch en 2026-08-06T20:05:00.000Z Verrica Pharmaceuticals Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/SGP/spyglass-pharma-q2-2026-financial-results BiopharmaWatch en 2026-08-06T20:05:00.000Z SpyGlass Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Updates https://www.biopharmawatch.com/news/RLMD/relmada-therapeutics-q2-2026-financial-results-update BiopharmaWatch en 2026-08-06T20:05:00.000Z Relmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/ECOR/electrocore-q2-2026-financial-results BiopharmaWatch en 2026-08-06T20:05:00.000Z electroCore Announces Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-q2-2026-financial-results-updates BiopharmaWatch en 2026-08-06T20:05:00.000Z Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates https://www.biopharmawatch.com/news/SRZN/surrozen-reports-q2-2026-financial-results-business-update BiopharmaWatch en 2026-08-06T20:05:00.000Z Surrozen Reports Second Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/EVMN/evommune-reports-q2-2026-results-business-highlights BiopharmaWatch en 2026-08-06T20:05:00.000Z Evommune Reports Second Quarter 2026 Financial Results and Provides Business Highlights https://www.biopharmawatch.com/news/PBYI/puma-biotechnology-q2-2026-financial-results BiopharmaWatch en 2026-08-06T20:05:00.000Z Puma Biotechnology Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/NTRA/natera-reports-q2-2026-financial-results BiopharmaWatch en 2026-08-06T20:05:00.000Z Natera Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/GRDN/guardian-pharmacy-services-q2-2026-results BiopharmaWatch en 2026-08-06T20:05:00.000Z Guardian Pharmacy Services Reports Second Quarter 2026 Financial Results; Raises Full-Year Guidance https://www.biopharmawatch.com/news/WGS/genedx-participate-upcoming-investor-conferences BiopharmaWatch en 2026-08-06T20:05:00.000Z GeneDx to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/OABI/omniab-reports-q2-2026-financial-results BiopharmaWatch en 2026-08-06T20:05:00.000Z OmniAb Reports Second Quarter 2026 Financial Results and Business Highlights https://www.biopharmawatch.com/news/TNDM/tandem-diabetes-care-q2-2026-results BiopharmaWatch en 2026-08-06T20:05:00.000Z Tandem Diabetes Care Announces Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/PRTA/prothena-reports-q2-2026-results BiopharmaWatch en 2026-08-06T20:05:00.000Z Prothena Reports Second Quarter 2026 Financial Results and Business Highlights https://www.biopharmawatch.com/news/HYPR/hyperfine-reports-q2-2026-financial-results BiopharmaWatch en 2026-08-06T20:05:00.000Z Hyperfine, Inc. Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/TLSI/trisalus-life-sciences-q2-2026-results BiopharmaWatch en 2026-08-06T20:05:00.000Z TriSalus Life Sciences Reports Second Quarter 2026 Results https://www.biopharmawatch.com/news/INGN/inogen-announces-q2-2026-financial-results BiopharmaWatch en 2026-08-06T20:05:00.000Z Inogen Announces Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/ASTH/astrana-health-q2-2026-results BiopharmaWatch en 2026-08-06T20:05:00.000Z Astrana Health, Inc. Reports Second Quarter 2026 Results https://www.biopharmawatch.com/news/AORT/artivion-reports-q2-2026-financial-results BiopharmaWatch en 2026-08-06T20:05:00.000Z Artivion Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/MTVA/metavia-reports-q2-2026-financial-results BiopharmaWatch en 2026-08-06T20:05:00.000Z MetaVia Reports Second Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/QDEL/quidelortho-q2-2026-financial-results BiopharmaWatch en 2026-08-06T20:05:00.000Z QuidelOrtho Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/SI/shoulder-innovations-q2-2026-financial-results BiopharmaWatch en 2026-08-06T20:05:00.000Z Shoulder Innovations Reports Second Quarter 2026 Financial Results and Raises Full Year Outlook https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-financial-results-q2-2026 BiopharmaWatch en 2026-08-06T20:05:00.000Z Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2026 https://www.biopharmawatch.com/news/CYRX/cryoport-reports-q2-2026-financial-results BiopharmaWatch en 2026-08-06T20:05:00.000Z Cryoport Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/ZYME/zymeworks-corporate-update-q2-2026-results BiopharmaWatch en 2026-08-06T20:05:00.000Z Zymeworks Provides Corporate Update and Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/OMDA/omada-health-q2-2026-results-ceo-transition BiopharmaWatch en 2026-08-06T20:03:00.000Z Omada Health Reports Second Quarter 2026 Results and Announces CEO Transition https://www.biopharmawatch.com/news/HCAT/health-catalyst-sale-vitalware-focus-healthcare-intelligence BiopharmaWatch en 2026-08-06T20:03:00.000Z Health Catalyst Completes Sale of Vitalware, Sharpening Its Focus as a Healthcare Intelligence Company https://www.biopharmawatch.com/news/BLFS/biolife-solutions-q2-2026-financial-results BiopharmaWatch en 2026-08-06T20:03:00.000Z BioLife Solutions Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/JANX/janux-therapeutics-q2-2026-financial-results BiopharmaWatch en 2026-08-06T20:02:00.000Z Janux Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights https://www.biopharmawatch.com/news/TXG/10x-genomics-q2-2026-financial-results BiopharmaWatch en 2026-08-06T20:02:00.000Z 10x Genomics Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/RCEL/avita-medical-q2-results-revenue-guidance BiopharmaWatch en 2026-08-06T20:02:00.000Z AVITA Medical Reports Second Quarter Results, Raises 2026 Revenue Guidance, and Expects Fourth Quarter Cash Flow Breakeven https://www.biopharmawatch.com/news/AGMB/agomab-half-year-2026-financial-results-outlook BiopharmaWatch en 2026-08-06T20:01:30.000Z Agomab Reports Half Year 2026 Financial Results and Confirms 2026 Outlook https://www.biopharmawatch.com/news/VYGR/voyager-reports-q2-2026-financial-results BiopharmaWatch en 2026-08-06T20:01:00.000Z Voyager Reports Second Quarter 2026 Financial and Operating Results https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-q2-2026-results-pipeline-progress BiopharmaWatch en 2026-08-06T20:01:00.000Z Arcturus Therapeutics Announces Second Quarter 2026 Financial Results and Pipeline Progress https://www.biopharmawatch.com/news/VSTM/verastem-oncology-q2-2026-financial-results BiopharmaWatch en 2026-08-06T20:01:00.000Z Verastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates https://www.biopharmawatch.com/news/DFTX/definium-therapeutics-q2-2026-financial-results BiopharmaWatch en 2026-08-06T20:01:00.000Z Definium Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-q2-2026-financial-results BiopharmaWatch en 2026-08-06T20:01:00.000Z Maravai LifeSciences Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/LCTX/lineage-cell-therapeutics-q2-2026-financial-results BiopharmaWatch en 2026-08-06T20:01:00.000Z Lineage Cell Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-closes-credit-facility-27-5-million BiopharmaWatch en 2026-08-06T20:01:00.000Z Verrica Pharmaceuticals Closes Credit Facility For Up To $27.5 Million in Non-Dilutive Growth Capital https://www.biopharmawatch.com/news/ASND/ascendis-reports-q2-2026-results-business-update BiopharmaWatch en 2026-08-06T20:01:00.000Z Ascendis to Report Second Quarter 2026 Financial Results and Provide Business Update on August 13, 2026 https://www.biopharmawatch.com/news/OM/outset-medical-reports-q2-2026-results BiopharmaWatch en 2026-08-06T20:01:00.000Z Outset Medical Reports Second Quarter 2026 Results https://www.biopharmawatch.com/news/CLDX/celldex-q2-2026-financial-results-update BiopharmaWatch en 2026-08-06T20:01:00.000Z Celldex Reports Second Quarter Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-business-update-q2-2026 BiopharmaWatch en 2026-08-06T20:01:00.000Z Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/SIGA/siga-reports-financial-results-q2-2026 BiopharmaWatch en 2026-08-06T20:01:00.000Z SIGA Reports Financial Results for Three and Six Months Ended June 30, 2026 https://www.biopharmawatch.com/news/XENE/xenon-reports-q2-2026-financial-results BiopharmaWatch en 2026-08-06T20:01:00.000Z Xenon Reports Q2 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/NXTC/nextcure-business-update-q2-2026-results BiopharmaWatch en 2026-08-06T20:01:00.000Z NextCure Provides Business Update and Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/ONC/beone-medicines-financial-results-q2-2026 BiopharmaWatch en 2026-08-06T20:00:00.000Z شركة BeOne Medicines تعلن عن النتائج المالية للربع الثاني من عام 2026 وآخر مستجدات الأعمال https://www.biopharmawatch.com/news/INMB/inmune-bio-q2-2026-results-regulatory-progress BiopharmaWatch en 2026-08-06T20:00:00.000Z INmune Bio Inc. Announces Second Quarter 2026 Results and Highlights Regulatory, Manufacturing and Clinical Progress https://www.biopharmawatch.com/news/INKT/mink-therapeutics-phase-2-trial-observations BiopharmaWatch en 2026-08-06T16:00:00.000Z MiNK Therapeutics Presents Early Observations from Ongoing Phase 2 Trial at the 2026 Military Health System Research Symposium https://www.biopharmawatch.com/news/CHE/chemed-quarterly-dividend-increase BiopharmaWatch en 2026-08-06T15:57:00.000Z Chemed Corporation Declares Quarterly Dividend of 70 Cents https://www.biopharmawatch.com/news/NRSN/neurosense-primec-pre-nds-health-canada-filing BiopharmaWatch en 2026-08-06T15:29:00.000Z NeuroSense Completes PrimeC Pre-NDS Process and Advances Toward December 2026 Filing with Health Canada https://www.biopharmawatch.com/news/GMAB/genmab-positive-phase-3-results-epcoritamab BiopharmaWatch en 2026-08-06T15:02:25.000Z Genmab Announces Financial Results for the First Half of 2026 https://www.biopharmawatch.com/news/CODX/co-diagnostics-fda-510k-premarket-notification BiopharmaWatch en 2026-08-06T13:30:00.000Z Co-Diagnostics Submits FDA 510(k) Premarket Notification for Upper Respiratory Point-of-Care Test https://www.biopharmawatch.com/news/CELZ/creative-medical-receives-patent-exosome-immunotherapy BiopharmaWatch en 2026-08-06T13:15:00.000Z Creative Medical Technology Holdings, Inc. Receives Notice of Allowance for New U.S. Patent Covering Exosome-Based Immunotherapy for Type 1 Diabetes, Deepening IP Protection Across Its MyeloCelz™, CELZ-101 and CELZ-201 Diabetes Platforms https://www.biopharmawatch.com/news/DARE/dare-bioscience-q2-2026-financial-results-update BiopharmaWatch en 2026-08-06T13:05:00.000Z Daré Bioscience to Host Second Quarter 2026 Financial Results and Company Update Conference Call and Webcast on August 13, 2026 https://www.biopharmawatch.com/news/APT/alpha-pro-tech-second-quarter-2026-results BiopharmaWatch en 2026-08-06T13:04:54.545Z Alpha Pro Tech, Ltd. Announces Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/KYNB/kyntra-bio-second-quarter-2026-financial-results BiopharmaWatch en 2026-08-06T13:00:00.000Z Kyntra Bio to Report Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/SILO/silo-pharma-qwikagents-collaborates-amazon-web-services BiopharmaWatch en 2026-08-06T12:50:00.000Z Silo Pharma Subsidiary QwikAgents Collaborates with Amazon Web Services Premier Tier Partner Caylent to Advance Enterprise AI Platform https://www.biopharmawatch.com/news/MLSS/milestone-scientific-q2-2026-financial-results-call BiopharmaWatch en 2026-08-06T12:47:00.000Z Milestone Scientific Schedules Second Quarter 2026 Financial Results Conference Call https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-q3-2026-financial-results-call BiopharmaWatch en 2026-08-06T12:45:00.000Z Outlook Therapeutics to Report Third Quarter Fiscal Year 2026 Financial Results and Host a Corporate Update Conference Call and Webcast on August 14, 2026 https://www.biopharmawatch.com/news/HCSG/armor-health-blair-county-prison-transition BiopharmaWatch en 2026-08-06T12:35:00.000Z Armor Health Successively Transitions Correctional Healthcare Services at Blair County Prison in Pennsylvania https://www.biopharmawatch.com/news/ICU/seastar-medical-second-quarter-results-2026 BiopharmaWatch en 2026-08-06T12:35:00.000Z SeaStar Medical to Report Second Quarter Financial Results on August 12, 2026 https://www.biopharmawatch.com/news/CELC/celcuity-q2-2026-financial-results-webcast BiopharmaWatch en 2026-08-06T12:34:00.000Z Celcuity Schedules Release of Second Quarter 2026 Financial Results and Webcast/Conference Call https://www.biopharmawatch.com/news/NAGE/niagen-bioscience-launches-tru-niagen-walmart BiopharmaWatch en 2026-08-06T12:34:00.000Z Niagen Bioscience Launches Tru Niagen on Walmart.com, Expanding Access and Diversifying Its E-commerce Marketplace Presence https://www.biopharmawatch.com/news/HCA/hca-healthcare-new-executive-appointments BiopharmaWatch en 2026-08-06T12:30:00.000Z HCA Healthcare Announces Dr. Michael Schlosser as Executive Vice President and Chief Clinical Officer; Names Charles Gressle President of New Ambulatory Operations Group https://www.biopharmawatch.com/news/CAI/caris-ai-predicts-breast-cancer-recurrence-risk BiopharmaWatch en 2026-08-06T12:30:00.000Z Caris Life Sciences, ECOG-ACRIN and NRG Oncology Study Demonstrates Multimodal AI Approach to Predict Late Distant Recurrence Risk in HR+ Early Breast Cancer https://www.biopharmawatch.com/news/SRXH/srx-global-fiscal-q3-2026-conference-call BiopharmaWatch en 2026-08-06T12:30:00.000Z SRX Global to Host Fiscal Third Quarter 2026 Conference Call on August 13 at 4:30 p.m. ET https://www.biopharmawatch.com/news/ONCO/onconetix-realbotix-emmy-robot-agreement BiopharmaWatch en 2026-08-06T12:30:00.000Z Onconetix Acquisition Target Realbotix Secures Agreement for Humanoid Robot Appearance on Emmy Award-Winning Streaming Series https://www.biopharmawatch.com/news/RNXT/renovorx-renovocath-sarcoma-treatment-expansion BiopharmaWatch en 2026-08-06T12:30:00.000Z RenovoRx Announces First Commercial Clinical Use of RenovoCath® in Sarcoma Patient Treatment, Marking Expansion of Targeted Drug-Delivery Device to Other Solid Tumors https://www.biopharmawatch.com/news/PPCB/propanc-biopharma-positive-preclinical-data-prp BiopharmaWatch en 2026-08-06T12:30:00.000Z Propanc Biopharma Announces Positive Preclinical and Early Translational Data for PRP Showing >90% Tumor Growth Inhibition and Significant Survival Benefit in Pancreatic Ductal Adenocarcinoma Models https://www.biopharmawatch.com/news/PRME/prime-medicine-q2-2026-financial-results-updates BiopharmaWatch en 2026-08-06T12:27:57.743Z Prime Medicine Reports Second Quarter 2026 Financial Results and Provides Business Updates https://www.biopharmawatch.com/news/HCTI/hcti-teyame-client-revenue-growth BiopharmaWatch en 2026-08-06T12:25:00.000Z HCTI's Teyame Delivers a Full Year of Client Revenue in Six Months; €2 Million in Target https://www.biopharmawatch.com/news/MBX/mbx-biosciences-q2-2026-results-highlights BiopharmaWatch en 2026-08-06T12:20:47.231Z MBX Biosciences Reports Second Quarter 2026 Financial Results and Corporate Highlights https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-q2-2026-financial-results-update BiopharmaWatch en 2026-08-06T12:19:36.259Z vTv Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/INKT/mink-therapeutics-q2-2026-financial-results-clinical-updates BiopharmaWatch en 2026-08-06T12:19:00.000Z MiNK Therapeutics to Report Second Quarter 2026 Financial Results, Provide Clinical Updates on agenT-797 in Lung Injury, and Highlight Important Business Updates https://www.biopharmawatch.com/news/CGON/cg-oncology-q2-2026-financial-results-business-updates BiopharmaWatch en 2026-08-06T12:15:00.000Z CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates https://www.biopharmawatch.com/news/NNOX/nano-x-imaging-8-million-offering BiopharmaWatch en 2026-08-06T12:10:42.564Z Nano-X Imaging Ltd. Announces Pricing of a $8 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules https://www.biopharmawatch.com/news/ASND/ascendis-coach-week-78-results-achondroplasia-update BiopharmaWatch en 2026-08-06T12:10:15.158Z Ascendis Announces COACH Week 78 Results and Provides Update on Achondroplasia Programs and YUVIWEL® Uptake in the U.S. https://www.biopharmawatch.com/news/ICCM/icecure-adventist-health-choicestudy-breast-cancer BiopharmaWatch en 2026-08-06T12:05:00.000Z IceCure Medical Adds Adventist Health as U.S. Clinical Site for its Post-Marketing "ChoICE" Study for Low-Risk Breast Cancer Cryoablation Treatment https://www.biopharmawatch.com/news/VIVS/vivosim-financial-listing-compliance-update BiopharmaWatch en 2026-08-06T12:05:00.000Z VivoSim Provides Financial and Listing Compliance Update https://www.biopharmawatch.com/news/HRMY/harmony-biosciences-piper-sandler-symposium BiopharmaWatch en 2026-08-06T12:05:00.000Z Harmony Biosciences to Participate in Piper Sandler Virtual CNS Symposium https://www.biopharmawatch.com/news/DCTH/delcath-systems-q2-2026-results BiopharmaWatch en 2026-08-06T12:01:00.000Z Delcath Systems Reports Second Quarter 2026 Results and Business Highlights https://www.biopharmawatch.com/news/MIRA/mira-positive-7-day-dog-study-results-skny-1 BiopharmaWatch en 2026-08-06T12:00:00.000Z MIRA Reports Positive 7-Day Dog Study Results for SKNY-1 https://www.biopharmawatch.com/news/ENSC/ensysce-acquisition-cy-biopharma-private-financing BiopharmaWatch en 2026-08-06T12:00:00.000Z Ensysce Biosciences Announces Acquisition of Cy Biopharma and up to $77 Million Private Financing https://www.biopharmawatch.com/news/ESTA/establishment-labs-reports-q2-2026-results BiopharmaWatch en 2026-08-06T12:00:00.000Z Establishment Labs® Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-corporate-update-q2-2026 BiopharmaWatch en 2026-08-06T12:00:00.000Z Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-business-progress-q2-2026 BiopharmaWatch en 2026-08-06T12:00:00.000Z Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/BRNS/barinthus-bio-q2-2026-financial-results-update BiopharmaWatch en 2026-08-06T12:00:00.000Z Barinthus Bio Reports Second Quarter 2026 Financial Results and Updates on Corporate Developments https://www.biopharmawatch.com/news/LNTH/q2-2026-lantheus-earnings-conference-call BiopharmaWatch en 2026-08-06T12:00:00.000Z Q2 2026 Lantheus Earnings Conference Call https://www.biopharmawatch.com/news/ALXO/alx-oncology-q2-2026-financial-results-update BiopharmaWatch en 2026-08-06T12:00:00.000Z ALX Oncology Reports Second Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/AUPH/aurinia-pharmaceuticals-financial-results-june-2026 BiopharmaWatch en 2026-08-06T12:00:00.000Z Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business Progress https://www.biopharmawatch.com/news/QTRX/quanterix-participate-canaccord-growth-conference-2026 BiopharmaWatch en 2026-08-06T12:00:00.000Z Quanterix To Participate in Canaccord Genuity Capital Markets 46th Annual Growth Conference on August 11-12 https://www.biopharmawatch.com/news/WHWK/whitehawk-therapeutics-q2-2026-results BiopharmaWatch en 2026-08-06T12:00:00.000Z Whitehawk Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights https://www.biopharmawatch.com/news/NVAX/novavax-q2-2026-financial-results BiopharmaWatch en 2026-08-06T12:00:00.000Z Novavax Reports Second Quarter 2026 Financial Results and Operational Highlights https://www.biopharmawatch.com/news/EWTX/edgewise-therapeutics-q2-2026-results BiopharmaWatch en 2026-08-06T12:00:00.000Z Edgewise Therapeutics Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/XTNT/xtant-medical-q2-2026-financial-results BiopharmaWatch en 2026-08-06T12:00:00.000Z Xtant Medical to Announce Second Quarter 2026 Financial Results on August 11, 2026 https://www.biopharmawatch.com/news/LNSR/lensar-report-second-quarter-2026-results BiopharmaWatch en 2026-08-06T12:00:00.000Z LENSAR® to Report Second Quarter 2026 Results on August 13th, 2026 https://www.biopharmawatch.com/news/VANI/vivani-medical-successful-dosing-slim-1-trial BiopharmaWatch en 2026-08-06T12:00:00.000Z Vivani Medical Announces Successful Dosing of All Participants in SLIM-1, a Phase 1 Trial Evaluating NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management https://www.biopharmawatch.com/news/ANNX/annexon-tanruprubart-gbs-forward-study-results BiopharmaWatch en 2026-08-06T12:00:00.000Z Annexon Reports First U.S. and European Patient Cohort of GBS FORWARD Study Demonstrated Rapid, Positive Clinical Responses in All Tanruprubart Treated Patients Within One Week https://www.biopharmawatch.com/news/TOVX/theriva-biologics-first-patient-dosed-virage2-trial BiopharmaWatch en 2026-08-06T12:00:00.000Z Theriva™ Biologics Announces First Patient Dosed in VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patients with Metastatic Pancreatic Ductal Adenocarcinoma https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-phase-1-data-pcrx-201 BiopharmaWatch en 2026-08-06T12:00:00.000Z Pacira BioSciences Announces Publication of Positive Two-Year Phase 1 Data For PCRX-201 in Annals of the Rheumatic Diseases https://www.biopharmawatch.com/news/BLTE/belite-bio-webcast-financial-results-august-2026 BiopharmaWatch en 2026-08-06T12:00:00.000Z Belite Bio to Host Webcast on August 13, 2026, to Discuss Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-q2-2026-results-update BiopharmaWatch en 2026-08-06T12:00:00.000Z Corbus Pharmaceuticals Reports Q2 2026 Financial Results and Provides a Corporate Update https://www.biopharmawatch.com/news/FBRX/argenx-tender-offer-forte-biosciences-acquisition BiopharmaWatch en 2026-08-06T11:48:00.000Z argenx Announces Commencement of Tender Offer to Acquire Forte Biosciences, Inc. https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-q2-2026-revenue-update BiopharmaWatch en 2026-08-06T11:42:25.550Z Iovance Biotherapeutics Reports Record Second Quarter 2026 Revenue of ~$99M, Business Achievements, and Corporate Updates https://www.biopharmawatch.com/news/KRRO/korro-reports-q2-2026-results-corporate-update BiopharmaWatch en 2026-08-06T11:34:54.940Z Korro Reports Second Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/IMCR/immunocore-q2-2026-financial-results-update BiopharmaWatch en 2026-08-06T11:34:11.368Z Immunocore reports second quarter financial results and provides a business update https://www.biopharmawatch.com/news/TLRY/tilray-launches-mollo-lite-blackberry-lemon-seltzer BiopharmaWatch en 2026-08-06T11:33:28.222Z Tilray Brands Expands THC Beverage Innovation with the Launch of Mollo Lite Blackberry Lemon Seltzer Multi-Pack https://www.biopharmawatch.com/news/SHC/sotera-health-q2-2026-results-outlook BiopharmaWatch en 2026-08-06T11:33:15.700Z Sotera Health Delivers Strong Second-Quarter and First-Half 2026 Results and Raises FY 2026 Outlook https://www.biopharmawatch.com/news/AVTX/avalon-therapeutics-q2-2026-financial-results BiopharmaWatch en 2026-08-06T11:33:01.049Z Avalo Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Updates https://www.biopharmawatch.com/news/PEPG/pepgen-reports-q2-2026-financial-results BiopharmaWatch en 2026-08-06T11:32:00.000Z PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights https://www.biopharmawatch.com/news/SABS/sab-bio-q2-2026-financial-results-highlights BiopharmaWatch en 2026-08-06T11:30:31.000Z SAB BIO Reports Q2 2026 Financial Results and Provides Business Highlights https://www.biopharmawatch.com/news/COLL/collegium-reports-q2-2026-financial-results BiopharmaWatch en 2026-08-06T11:30:00.000Z Collegium Reports Second Quarter 2026 Financial Results and Highlights Recent Company Progress https://www.biopharmawatch.com/news/PEPG/pepgen-advance-pgn-edodm1-highest-dose-cohort BiopharmaWatch en 2026-08-06T11:30:00.000Z PepGen to Advance PGN-EDODM1 Into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review https://www.biopharmawatch.com/news/AGEN/agenus-reports-q2-2026-results-phase-3-robbin-trial BiopharmaWatch en 2026-08-06T11:30:00.000Z Agenus Reports Second Quarter 2026 Results and Advances Phase 3 ROBBIN Trial of BOT+BAL in Neoadjuvant MSS Colon Cancer https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-q2-2026-financial-results-call BiopharmaWatch en 2026-08-06T11:30:00.000Z ADC Therapeutics to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026 https://www.biopharmawatch.com/news/NUVB/nuvation-bio-q2-2026-financial-results-update BiopharmaWatch en 2026-08-06T11:30:00.000Z Nuvation Bio Reports Second Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/CRON/cronos-group-q2-2026-results BiopharmaWatch en 2026-08-06T11:30:00.000Z Cronos Group Reports 2026 Second Quarter Results https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-q2-2026-financial-results BiopharmaWatch en 2026-08-06T11:30:00.000Z Lexicon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Clinical Updates https://www.biopharmawatch.com/news/BIVI/biovie-sunrise-pd-trial-results-bezisterim-parkinsons BiopharmaWatch en 2026-08-06T11:30:00.000Z BioVie Announces Topline Results of Phase 2 SUNRISE-PD Trial of Bezisterim in Early Parkinson’s Disease https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-q2-2026-financial-results-update BiopharmaWatch en 2026-08-06T11:30:00.000Z Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-q2-2026-financial-results-call BiopharmaWatch en 2026-08-06T11:30:00.000Z Abeona Therapeutics® to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026 https://www.biopharmawatch.com/news/IFRX/inflarx-reports-q2-2026-results-and-milestones BiopharmaWatch en 2026-08-06T11:30:00.000Z InflaRx Reports Second Quarter 2026 Results and Highlights Key Achievements and Expected Milestones https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-presentation-canaccord-conference BiopharmaWatch en 2026-08-06T11:25:00.000Z Alterity Therapeutics to Present at the 46th Annual Canaccord Genuity Growth Conference https://www.biopharmawatch.com/news/IRWD/ironwood-pharmaceuticals-raises-2026-financial-guidance BiopharmaWatch en 2026-08-06T11:05:00.000Z Ironwood Pharmaceuticals Raises 2026 Full-Year Financial Guidance Building on Strong Second Quarter Results https://www.biopharmawatch.com/news/RGNX/regenxbio-reports-q2-2026-results-highlights BiopharmaWatch en 2026-08-06T11:05:00.000Z REGENXBIO Reports Second Quarter 2026 Financial Results and Operational Highlights https://www.biopharmawatch.com/news/BHC/bausch-health-ceo-joins-bausch-lomb-board BiopharmaWatch en 2026-08-06T11:04:00.000Z Bausch Health CEO Thomas J. Appio Joins Bausch + Lomb Board https://www.biopharmawatch.com/news/TARS/tarsus-reports-q2-2026-results-growth BiopharmaWatch en 2026-08-06T11:03:52.000Z Tarsus Reports Second Quarter 2026 Financial Results, Advances Next Phase of Growth https://www.biopharmawatch.com/news/OCGN/ocugen-business-update-q2-2026-results BiopharmaWatch en 2026-08-06T11:02:00.000Z Ocugen Provides Business Update with Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/TARS/tarsus-pharmaceuticals-125-million-private-placement BiopharmaWatch en 2026-08-06T11:02:00.000Z Tarsus Pharmaceuticals Announces Oversubscribed $125.0 Million Private Placement Equity Financing https://www.biopharmawatch.com/news/DTIL/precision-biosciences-q2-2026-results-update BiopharmaWatch en 2026-08-06T11:01:00.000Z Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-business-progress-q2-2026 BiopharmaWatch en 2026-08-06T11:01:00.000Z Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/TARS/tarsus-acquires-alkeus-pharmaceuticals-eye-care BiopharmaWatch en 2026-08-06T11:01:00.000Z Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals and Advance Eye Care Leadership Position https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-q2-2026-update BiopharmaWatch en 2026-08-06T11:00:32.000Z Foghorn Therapeutics Provides Second Quarter 2026 Financial and Corporate Update https://www.biopharmawatch.com/news/INSM/insmed-reports-q2-2026-financial-results BiopharmaWatch en 2026-08-06T11:00:00.000Z Insmed Reports Second-Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/GENB/generate-biomedicines-q2-2026-financial-results-update BiopharmaWatch en 2026-08-06T11:00:00.000Z Generate Biomedicines Inc. Reports Second Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/SRRK/scholar-rock-q2-2026-financial-results BiopharmaWatch en 2026-08-06T11:00:00.000Z Scholar Rock Reports Second Quarter 2026 Financial Results and Recent Business Highlights https://www.biopharmawatch.com/news/ZTS/zoetis-appoints-jay-saccaro-cfo-coo BiopharmaWatch en 2026-08-06T11:00:00.000Z Zoetis Appoints Jay Saccaro as Chief Financial Officer and Chief Operating Officer https://www.biopharmawatch.com/news/ZTS/zoetis-announces-q2-2026-results BiopharmaWatch en 2026-08-06T11:00:00.000Z Zoetis Announces Second Quarter 2026 Results https://www.biopharmawatch.com/news/CMPS/compass-pathways-participate-canaccord-growth-conference BiopharmaWatch en 2026-08-06T11:00:00.000Z Compass Pathways to Participate in Canaccord Genuity's 46th Annual Growth Conference on August 12, 2026 https://www.biopharmawatch.com/news/AMLX/amylyx-pharmaceuticals-q2-2026-financial-results BiopharmaWatch en 2026-08-06T11:00:00.000Z Amylyx Pharmaceuticals Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/BLCO/bausch-lomb-board-update-guidance BiopharmaWatch en 2026-08-06T11:00:00.000Z Bausch + Lomb Announces Board of Directors Update, Reaffirms Guidance https://www.biopharmawatch.com/news/XERS/xeris-biopharma-q2-2026-financial-results BiopharmaWatch en 2026-08-06T11:00:00.000Z Xeris Biopharma Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/BHVN/biohaven-appoints-john-yetimoglu-board-directors BiopharmaWatch en 2026-08-06T11:00:00.000Z Biohaven Appoints Technology Investor John Yetimoglu to Board of Directors https://www.biopharmawatch.com/news/KOD/kodiak-sciences-phase-3-peek-trial-enrollment-completed BiopharmaWatch en 2026-08-06T11:00:00.000Z Kodiak Sciences Completes Enrollment in First Pivotal Cohort in the Phase 3 PEAK Trial of KSI-101 for Macular Edema Secondary to Inflammation and Reaffirms Topline Clinical Data Release Remains on Track for December 2026 https://www.biopharmawatch.com/news/EVH/evolent-announces-second-quarter-2026-results BiopharmaWatch en 2026-08-06T11:00:00.000Z Evolent Announces Second Quarter 2026 Results https://www.biopharmawatch.com/news/MDT/medtronic-ce-mark-indication-sphere-9-catheter BiopharmaWatch en 2026-08-06T11:00:00.000Z Medtronic announces expanded CE Mark indication for Affera™ Mapping and Ablation System and Sphere-9™ Catheter for treatment of ventricular arrhythmias https://www.biopharmawatch.com/news/ROIV/roivant-financial-results-q1-2026-business-update BiopharmaWatch en 2026-08-06T11:00:00.000Z Roivant Reports Financial Results for the First Quarter Ended June 30, 2026, and Provides Business Update https://www.biopharmawatch.com/news/IMVT/immunovant-corporate-updates-financial-results-q2-2026 BiopharmaWatch en 2026-08-06T11:00:00.000Z Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026 https://www.biopharmawatch.com/news/HROW/harrow-acquires-global-rights-tyrvaya-nasal-spray BiopharmaWatch en 2026-08-06T11:00:00.000Z Harrow Acquires Global Rights to TYRVAYA®, the First and Only FDA-Approved Nasal Spray for Dry Eye Disease https://www.biopharmawatch.com/news/AMS/american-shared-hospital-services-q2-2026-call BiopharmaWatch en 2026-08-06T11:00:00.000Z American Shared Hospital Services Announces Second Quarter 2026 Financial Results Conference Call https://www.biopharmawatch.com/news/SION/sionna-therapeutics-q2-2026-financial-results BiopharmaWatch en 2026-08-06T11:00:00.000Z Sionna Therapeutics Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-q2-2026-financial-results BiopharmaWatch en 2026-08-06T11:00:00.000Z Monte Rosa Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates https://www.biopharmawatch.com/news/CLYM/climb-bio-q2-2026-financial-results-updates BiopharmaWatch en 2026-08-06T11:00:00.000Z Climb Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-q2-2026-results BiopharmaWatch en 2026-08-06T11:00:00.000Z Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates https://www.biopharmawatch.com/news/CGEM/cullinan-therapeutics-update-q2-2026-results BiopharmaWatch en 2026-08-06T11:00:00.000Z Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/IRD/opus-genetics-financial-results-q2-2026-update BiopharmaWatch en 2026-08-06T11:00:00.000Z Opus Genetics Announces Financial Results for Second Quarter 2026 and Provides Corporate Update https://www.biopharmawatch.com/news/RNAC/cartesian-therapeutics-q2-2026-update BiopharmaWatch en 2026-08-06T11:00:00.000Z Cartesian Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-q2-2026-results-update BiopharmaWatch en 2026-08-06T10:59:00.000Z Aclaris Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate and Clinical Update https://www.biopharmawatch.com/news/VTRS/viatris-reports-q2-2026-financial-results BiopharmaWatch en 2026-08-06T10:59:00.000Z Viatris Reports Second-Quarter 2026 Financial Results https://www.biopharmawatch.com/news/PHVS/assessment-aae-c1inh-disease-burden-clinical-trial-endpoints BiopharmaWatch en 2026-08-06T10:50:00.000Z Assessment of AAE-C1INH Disease Burden and Validation of Clinical Trial Endpoints Published in Frontiers in Immunology https://www.biopharmawatch.com/news/WRBY/warby-parker-q2-2026-results BiopharmaWatch en 2026-08-06T10:45:00.000Z Warby Parker Announces Second Quarter 2026 Results https://www.biopharmawatch.com/news/MRK/fda-accepts-sbla-enflonsia-rsv-indication-update BiopharmaWatch en 2026-08-06T10:45:00.000Z U.S. FDA Accepts sBLA for ENFLONSIA™ (clesrovimab-cfor) to Update its Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease Indication to Include Children Under Two Years at Increased Risk for Severe RSV for Their Second Season https://www.biopharmawatch.com/news/ZLAB/zai-lab-q2-2026-financial-results-updates BiopharmaWatch en 2026-08-06T10:30:00.000Z Zai Lab Announces Second Quarter 2026 Financial Results and Recent Corporate Updates https://www.biopharmawatch.com/news/TFX/teleflex-q2-2026-financial-results-outlook BiopharmaWatch en 2026-08-06T10:30:00.000Z Teleflex Reports Second Quarter Financial Results and Full Year 2026 Outlook https://www.biopharmawatch.com/news/CMPS/compass-pathways-va-psilocybin-study BiopharmaWatch en 2026-08-06T10:30:00.000Z Compass Pathways Working with U.S. Department of Veterans Affairs for Investigational Study of Psilocybin https://www.biopharmawatch.com/news/ENOV/enovis-second-quarter-2026-results BiopharmaWatch en 2026-08-06T10:05:00.000Z Enovis Announces Second Quarter 2026 Results https://www.biopharmawatch.com/news/OSCR/oscar-health-record-financial-results-h1-2026 BiopharmaWatch en 2026-08-06T10:00:00.000Z Oscar Health Announces Record Financial Results for First Half 2026 and Raises Full Year 2026 Outlook https://www.biopharmawatch.com/news/PRVA/privia-health-strong-q2-2026-results BiopharmaWatch en 2026-08-06T10:00:00.000Z Privia Health Reports Strong Second Quarter and Year-to-Date 2026 Results https://www.biopharmawatch.com/news/ODTX/evotec-odyssey-ai-collaboration-autoimmune-diseases BiopharmaWatch en 2026-08-06T06:16:00.000Z Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases https://www.biopharmawatch.com/news/ONC/beone-medicines-q2-2026-financial-results-update BiopharmaWatch en 2026-08-06T01:44:00.000Z Samenvatting: BeOne Medicines maakt de financiële resultaten over het tweede kwartaal van 2026 bekend en geeft een update over de bedrijfsactiviteiten https://www.biopharmawatch.com/news/TARS/tarsus-reports-q2-2026-results-webcast BiopharmaWatch en 2026-08-06T00:02:00.000Z Tarsus to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026 https://www.biopharmawatch.com/news/TAK/fda-approves-takeda-orzeyful-narcolepsy-treatment BiopharmaWatch en 2026-08-05T22:10:00.000Z U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1 https://www.biopharmawatch.com/news/BIOA/bioage-labs-reports-q2-2026-financial-results BiopharmaWatch en 2026-08-05T20:50:00.000Z BioAge Labs Reports Second Quarter 2026 Financial Results and Provides Business Updates